Please login to the form below

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

Bayer pins hopes on five potential blockbusters

Bayer pins hopes on five potential blockbusters. Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223
FDA fast-tracks Bayer's prostate cancer radiotherapy

FDA fast-tracks Bayer's prostate cancer radiotherapy. Priority review for radium-223 dichloride, formerly called Alpharadin. ... The FDA granted priority review status to radium-223 dichloride - formerly called Alpharadin - for the treatment of
New hope for castration-resistant prostate cancer

Another bone-targeting agent in phase III trials of use in patients with CRPC and bone metastases is radium-223 chloride (Alpharadin; Algeta, Bayer Healthcare), a first-in-class, highly targeted
Developing drugs to conquer cancer

Bayer HealthCare discussed phase III results concerning regorafenib in gastrointestinal stromal tumour (GIST) and in colorectal cancer, as well as the final overall survival analysis of radium-223 (Alpharadin) data in
Bayer raises 2012 forecasts on increasing revenues

Bayer has previously highlighted four potential blockbusters in its late-stage pipeline, including Xarelto, Eylea (aflibercept) for wet age-related macular degeneration (AMD) and two cancer drugs, namely alpharadin for bone

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Associate Medical Director: Highly Competitive

Associate Director: £75, 000-90, 000

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Senior Account Executive, London, Medical Communications: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Project / Account Manager (Medical Education): Salary TBC

Senior Systematic Review Analyst - Oxford: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager / Account Director: Competative

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Production Manager – Healthcare Communications: DOE

Director, Market Access / HEOR - North-West: Negotiable

Events Manager – Med Comms – Surrey: Salary TBC

Account Director: £48, 000 - £60, 000

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

New Business Director - PR: Competitive Salary and benefits

Account Director: Excellent benefits

Senior Account Director development role to Business Director, H...: Excellent package

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...